Tim Haines is listed by Abingworth as an Executive Partner on its Executive Team, based in London, with stated expertise in venture capital and VIPEs. His firm bio states he has more than 40 years of international management experience in the life sciences industry in both public and private companies, that he joined Abingworth in 2005 as Partner and later became Chairman and Managing Partner, and that he was previously start-up Chief Executive of Astex Therapeutics, which was acquired by Otsuka Pharmaceuticals. Earlier in his career he held Chief Executive roles at divisions of Datascope Corp and at Thackray Inc, and was General Manager of Baxter UK. Abingworth states he has taken chair and board roles across companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies and Sientra, and that he sits on the Investment Advisory Board of Oxford University Innovation. He holds a BSc from Exeter University and an MBA from INSEAD.
Held Chief Executive roles at divisions of Datascope Corp and at Thackray Inc, and was General Manager of Baxter UK.
null
Served as start-up Chief Executive of Astex Therapeutics, which was later acquired by Otsuka Pharmaceuticals.
2005
Joined Abingworth as a Partner, later becoming Chairman and Managing Partner.
2022
The Carlyle Group agreed on 11 April to acquire Abingworth LLP, with the acquisition completed on 3 August.
null
Listed by Abingworth as Executive Partner, with expertise in venture capital and VIPEs, and serving on the Investment Advisory Board of Oxford University Innovation.